Short answer
Charles River Laboratories (CRL) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 26, 2026. Quarterly revenue was $983M (down 2.2% year over year) with net income of $333M.
Q3 2026 key financials · XBRL
- Revenue
- $983M
- −2.2% YoY · −2.1% QoQ
- Net income
- $333M
- +512.0% YoY · +22574.2% QoQ
- Operating margin
- 20.6%
- EPS (diluted)
- $6.82
- +520.0% YoY · +17150.0% QoQ
Source: XBRL data from the Charles River Laboratories (CRL) Q3 2026 10-Q on SEC EDGAR. USD.
Charles River Laboratories Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $982.7M, down $22.1M or 2.2% YoY
- Operating margin 20.6% vs 13.3% YoY, operating income $202.6M vs $133.8M
- Best segment: Manufacturing revenue $178.9M, operating margin 35.7% vs 20.9%
- Worst segment: RMS revenue $207.5M, down 2.8% YoY, driven by Cell Solutions divestiture
- Cash $200.4M vs $213.8M, operating cash flow $474.9M vs $590.1M, $300.0M stock repurchases and $467.3M acquisitions through nine months
Risk Factors
- No material changes to 2025 Form 10-K risk factors
- Q1 10-Q risk factor incorporated by reference, with no details repeated this quarter
- Additional unknown or currently immaterial risks could materially adversely affect results
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Charles River Laboratories quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.